Prognostic value of immune checkpoint molecules in breast cancer

doi:10.1042/BSR20201054

	Prognostic value of immune checkpoint molecules in breast cancer
	Fang, Jun 3,4,5; Chen, Feng 2,5; Liu, Dong 3,4,5; Gu, Feiying 3,4,5; Chen, Zhigang 1; Wang, Yuezhen 3,4,5
刊名	BIOSCIENCE REPORTS
	2020-07-07
卷号	40
ISSN号	0144-8463
DOI	10.1042/BSR20201054
通讯作者	Wang, Yuezhen(wangyuezhen_zch@126.com)
英文摘要	Immune checkpoint blockade treatments bring remarkable clinical benefits to fighting sev-eral solid malignancies. However, the efficacy of immune checkpoint blockade in breast cancer remains controversial. Several clinical trials of immune checkpoint blockades fo-cused on the effect of CTLA4 and PD1/PDL1 checkpoint inhibitors on breast cancer. Only a small portion of patients benefited from these therapies. Here we systematically investi-gated the expression of 50 immune checkpoint genes, including ADORA2A, LAG-3, TIM-3, PD1, PDL1, PDL2, CTLA-4, IDO1, B7-H3, B7-H4, CD244, BTLA, TIGIT, CD80, CD86, VISTA, CD28, ICOS, ICOSLG, HVEM, CD160, LIGHT, CD137, CD137L, OX40, CD70, CD27, CD40, CD40LG, LGALS9, GITRL, CEACAM1, CD47, SIRPA, DNAM1, CD155, 2B4, CD48, TMIGD2, HHLA2, BTN2A1, DC-SIGN, BTN2A2, BTN3A1, BTNL3, BTNL9, CD96, TDO, CD200 and CD200R, in different subtypes of breast cancer and assessed their prognostic value. The results showed that the expression patterns of these 50 immune checkpoint genes were distinct in breast cancer. High expression of B7-H3 mRNA was significantly associated with worse overall survival (OS), especially in patients with luminal A and luminal B breast cancer. The mRNA expression levels of TIM-3, ADORA2A, LAG3, CD86, CD80, PD1 and IDO1 had no relationship with OS in breast cancer. High expression levels of CTLA-4 and TIGIT were correlated with favorable prognosis in breast cancer. Interestingly, we observed that B7-H3 expression was negatively correlated with the efficacy of cyclophosphamide (CTX). In sum-mary, our study suggested that B7-H3 has potential prognostic value in breast cancer and is a promising target for immune therapy.
资助项目	Natural Science Foundation of Zhejiang province[LY19H160004] ; Bureau of Public Health of Zhejiang province[2017192527]
WOS关键词	CTLA-4 BLOCKADE ; B7-H3 ; IPILIMUMAB ; INHIBITION ; EXPRESSION ; ANTIBODY
WOS研究方向	Biochemistry & Molecular Biology ; Cell Biology
语种	英语
出版者	PORTLAND PRESS LTD
WOS记录号	WOS:000558064800001
资助机构	Natural Science Foundation of Zhejiang province ; Bureau of Public Health of Zhejiang province
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/70729]
专题	中国科学院合肥物质科学研究院
通讯作者	Wang, Yuezhen
作者单位	1.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Surg Oncol, Hangzhou, Zhejiang, Peoples R China 2.Univ Chinese Acad Sci, Inst Canc Res & Basic Med Sci, Chinese Acad Sci, Dept Breast Tumor Surg,Canc Hosp,Zhejiang Canc Ho, Hangzhou, Zhejiang, Peoples R China 3.Key Lab Radiat Oncol Zhejiang Prov, Hangzhou 310022, Zhejiang, Peoples R China 4.Univ Chinese Acad Sci, Dept Radiat Oncol, Zhejiang Canc Hosp, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 5.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou 310022, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Fang, Jun,Chen, Feng,Liu, Dong,et al. Prognostic value of immune checkpoint molecules in breast cancer[J]. BIOSCIENCE REPORTS,2020,40.
APA	Fang, Jun,Chen, Feng,Liu, Dong,Gu, Feiying,Chen, Zhigang,&Wang, Yuezhen.(2020).Prognostic value of immune checkpoint molecules in breast cancer.BIOSCIENCE REPORTS,40.
MLA	Fang, Jun,et al."Prognostic value of immune checkpoint molecules in breast cancer".BIOSCIENCE REPORTS 40(2020).